Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3052494 | 0.89 | ADORA2A (0.48) | ADORA2AADORA1ALDH1A1TP53HPGD | |
| SCHEMBL3057679 | 0.88 | ADORA2A (0.48) | ADORA2AADORA1TP53ADORA2BADORA3 | |
| SCHEMBL2825553 | 0.88 | ADORA2A (0.63) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL3052214 | 0.87 | ADORA2A (0.61) | ADORA2AADORA1ALDH1A1TP53TSHR | |
| SCHEMBL5943369 | 0.87 | ADORA2A (0.52) | ADORA2AADORA1TP53ADORA2BADORA3 | |
| SCHEMBL5997854 | 0.82 | ALDH1A1 (0.48) | ADORA2AADORA1ALDH1A1HPGDTSHR | |
| SCHEMBL3055076 | 0.82 | ALDH1A1 (0.60) | ADORA2AADORA1ALDH1A1TP53HPGD | |
| SCHEMBL3042835 | 0.81 | ADORA2A (0.45) | ADORA2AADORA1ALDH1A1TP53TSHR | |
| SCHEMBL3051987 | 0.80 | SMN1; SMN2 (0.53) | ALDH1A1TP53HPGDTSHRSMN1; SMN2 | |
| SCHEMBL6691863 | 0.78 | ADORA2A (0.52) | ADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1455792-B1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-04-18 | — | — | EP | claimed |
| US-7019001-B2 | Substituted benzothiazole amide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-03-28 | — | — | US | claimed |
| US-20040229893-A1 | Substituted benzothiazole amide derivatives | FLOHR ALEXANDER (CH) | 2004-11-18 | — | — | US | claimed |
| EP-1455792-A1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-15 | — | — | EP | claimed |
| US-20030149036-A1 | Substituted benzothiazole amide derivatives | HOFFMAN-LA ROCHE INC. | 2003-08-07 | — | — | US | claimed |
| WO-2003049741-A1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-19 | — | — | WO | claimed |
| EP-1303272-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | claimed |
| WO-2001097786-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-12-27 | — | — | WO | claimed |
| EP-1455792-B1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-04-18 | — | — | EP | disclosed |
| US-7019001-B2 | Substituted benzothiazole amide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20040229893-A1 | Substituted benzothiazole amide derivatives | FLOHR ALEXANDER (CH) | 2004-11-18 | — | — | US | disclosed |
| EP-1455792-A1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-15 | — | — | EP | disclosed |
| US-6727247-B2 | ADENOSINE RECEPTOR LIGANDS IN A METHOD OF TREATMENT, CONTROL, OR PREVENTION OF CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMAN-LA ROCHE INC. | 2004-04-27 | — | — | US | disclosed |
| US-20030149036-A1 | Substituted benzothiazole amide derivatives | HOFFMAN-LA ROCHE INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003049741-A1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149036-A1 | Substituted benzothiazole amide derivatives | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885ADORA1 2/4885ALDH1A1 512/4885 |
| US-20040229893-A1 | Substituted benzothiazole amide derivatives | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885ADORA1 2/4885ALDH1A1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.